With concerns over waning vaccine immunity and the potential for a surge in cases in the fall, these results should be celebrated. Though some are worried about what role COVID will have in our daily lives when summer draws to a close, a highly effective bivalent vaccine could be the first step on the roadmap to annual COVID treatments and a return to normality.
Whilst Moderna deserves credit for developing and rolling out an effective COVID vaccine with astounding speed, they are now profiteering from the virus. The pharmaceutical giant made $7.3B in after-tax profits in the first three quarters of 2021, now it is seeking further authorization to continue global sales.
There is a 50% chance that at least 95.3k people will be reported to have died per year from COVID-19 on average between 2022-2025 in the US, according to the Metaculus prediction community